Pharmacogenomics for Adverse Drug Reactions

Pharmacogenomics have long held the promise of using personalized information for drug selection to maximize efficacy and minimize adverse reactions. A new study evaluates the routine use of pharmacogenomic testing to improve safety in a wide range of medications. Join host, Geoff Wall, as he evaluates personalized medicine.The GameChangerMost studies using routine pharmacogenomic testing in clinical practice have not been significant. However, a new study found a 12 panel pharmacogenomic test did decrease the incidence of patient reported adverse effects compared to usual care. Several limitations still exist preventing widespread implementation.Show Segments00:00 - Introductions01:38 - Genomic Guided Therapy to Date05:05 - Importance of Genomic Variations08:37 - Looking at the Study21:20 - The GameChanger: Swen et al Results27:50 - Connecting to Practice: Current Barriers to Pharmacogenomic Testing30:38- Closing RemarksHostGeoff Wall, PharmD, BCPS, FCCP, CGPProfessor of Pharmacy Practice, Drake UniversityInternal Medicine/Critical Care, UnityPoint HealthReferences and ResourcesA 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. Clinical Pharmacogenomics Implementation Consortium. Redeem your CPE hereCPE (Pharmacist)Get a membership & earn CE for GameChangers Podcast episodes (30 mins/episode)Pharmacists: Get a membershipCE InformationLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe current barriers to routine use of pharmacogenomic testing2. Discuss issues and results of the Swen et al study on pharmacogenomics0.05 CEU/0.5 HrUAN: 0107-0000-23-118-H01-PInitial release date: 03/20/2023Expiration date: 03/20/2024Additional CPE and CME details can be found here.Follow CEimpact on Social Media:LinkedInInstagram